Digital sovereignty is the ultimate strategic lever for innovation. It propels organizations beyond compliance into true operational freedom where you, not your cloud provider, dictates your business continuity. Red Hat believes that sovereignty shouldn’t be a wall but a foundation for the freedom to choose where and how you run your workloads. To accelerate this […] The post How sovereign is your strategy? Introducing the Red Hat Sovereignty Readiness Assessment tool appeared first on Web-Release.

    Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.